RecruitingPhase 1NCT06917885

CUE-102 in Recurrent Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
David Reardon, MD
Principal Investigator
David Reardon, MD
Dana-Farber Cancer Institute
Intervention
CUE-102(biological)
Enrollment
18 target
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (2)

Collaborators

Cue Biopharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06917885 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials